Johnson & Johnson said it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes https://t.co/esl7QarjXl ...

Core Insights - Abbott Laboratories is expected to report third-quarter earnings on October 15, 2025, with an anticipated EPS of $1.30, reflecting a 7.4% increase year-over-year, and projected revenue of $11.4 billion, up from $10.63 billion a year ago [1][6] Financial Performance - The anticipated EPS of $1.30 represents an 8.3% year-over-year growth, indicating strong performance despite a recent stock decline of 0.6%, closing at $132.57 [2] - Abbott's financial metrics include a price-to-earnings (P/E) ratio of approximately 16.36 and a price-to-sales ratio of about 5.30, suggesting a favorable market valuation [4] - The company's debt-to-equity ratio stands at 0.27, indicating a relatively low level of debt, while a current ratio of 1.82 reflects strong liquidity to cover short-term liabilities [4] Strategic Focus - Abbott's strategic emphasis on expanding its diabetes care solutions is identified as a key driver for future growth, transitioning from devices to comprehensive, data-driven care solutions [3][6] - This strategic move is expected to enhance Abbott's competitive edge and contribute to its long-term success in the healthcare industry [3] Analyst Insights - The consensus earnings estimate for Abbott has been slightly adjusted downward by 0.1% over the past month, reflecting analysts' reassessment of initial projections [5] - This adjustment could influence investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [5]

Core Insights - Johnson & Johnson raised its full-year sales outlook due to gains in both its prescription-drug and medical-device businesses in the latest quarter [1] Company Performance - The company reported an increase in sales across its prescription-drug segment, contributing positively to the overall financial outlook [1] - Gains in the medical-device business also played a significant role in enhancing the company's sales projections for the year [1]

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20... ...

Core Viewpoint - Johnson & Johnson reported strong performance in Q3 2025, driven by a robust portfolio and progress in key therapeutic areas, indicating a new era of growth and innovation [1]. Overall Financial Results - The company does not provide GAAP financial measures on a forward-looking basis due to uncertainties related to legal proceedings and other factors [5]. Regional Sales Results - Specific regional sales results were not detailed in the provided content. Segment Sales Results Innovative Medicine - Worldwide operational sales grew by 5.3%, with net acquisitions and divestitures contributing positively by 1.6% due to CAPLYTA [3]. - Key growth drivers included DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience [3]. - Growth was partially offset by a negative impact of approximately 1,070 basis points from STELARA in Immunology and IMBRUVICA in Oncology [3]. MedTech - Worldwide operational sales increased by 5.6%, with net acquisitions and divestitures negatively impacting growth by 0.1% [4]. - Growth was primarily driven by electrophysiology products, Abiomed, Shockwave in Cardiovascular, wound closure products in General Surgery, and Surgical Vision [4]. Notable Announcements in the Quarter - The company encourages reviewing its disclosures filed with the Securities and Exchange Commission for additional context [7]. Webcast Information - Johnson & Johnson will conduct a conference call with investors to discuss the earnings release, accessible via their website [8]. About Johnson & Johnson - The company emphasizes its commitment to healthcare innovation, aiming to prevent, treat, and cure complex diseases through its expertise in Innovative Medicine and MedTech [9].

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson said Tuesday that it plans to spin out its orthopedics business, creating a standalone company that would compete with firms like Stryker and Zimmer Biomet. The healthcare giant said the decision is intended to focus its medtech unit on higher-growth and higher-margin markets. The spinout, which will be called DePuy Synthes, is expected to happen in ...

Electromed, Inc. to Participate in LD Micro Main Event XIXManagement will present Monday, October 20, 2025 at 10:00 am PTOctober 13, 2025 4:30 PM EDT | Source: LD MicroNew Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announced that Company management will participate in the LD Micro Main Event XIX Conference being held October 19-21, 2025 in San Diego. ...

Key Takeaways INSP reported positive Inspire V data with enhanced safety and better patient adherence.INSP's trials showed 20% shorter surgical times and superior AHI improvement versus Inspire IV.INSP's U.S. release confirmed efficient implantation, stable therapy use and no serious adverse events. Inspire Medical Systems (INSP) recently unveiled promising clinical data from its Inspire V system at the ISSS and AAO-HNS meetings, showcasing strong safety, enhanced respiratory sensing and improved patient ad ...

Key Takeaways BDX enrolled the first patient in the XTRACT Registry to evaluate the Rotarex Catheter System for PAD.BDX's Rotarex system combines atherectomy and thrombectomy functions to treat PAD lesions effectively.BD aims to boost its PI business and improve patient outcomes through real-world evidence from the registry.Becton, Dickinson and Company (BDX) , popularly known as BD, announced the enrollment of the first patient in the XTRACT Registry. It is a prospective, multi-center, single-arm, post-mar ...

Core Insights - DexCom, Inc. is valued at a market cap of $25.5 billion and specializes in continuous glucose monitoring systems for diabetes management [1] - The company is expected to announce its fiscal Q3 earnings for 2025 on October 30, 2023 [1] Financial Performance - Analysts predict a profit of $0.57 per share for Q3 2025, representing a 26.7% increase from $0.45 per share in the same quarter last year [2] - For fiscal 2025, DexCom is expected to report a profit of $2.04 per share, up 24.4% from $1.64 per share in fiscal 2024, with further growth anticipated to $2.56 in fiscal 2026 [3] Stock Performance - DexCom shares have declined 4.7% over the past 52 weeks, underperforming the S&P 500 Index's 14.2% return, but have outperformed the Health Care Select Sector SPDR Fund's 7.5% decline [4] - Following better-than-expected Q2 results, DexCom's shares fell 9.3% in the subsequent trading session despite a 15.2% year-over-year revenue increase to $1.2 billion [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for DexCom, with 20 out of 27 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and six indicating "Hold" [6] - The mean price target for DexCom is $100.24, suggesting a potential upside of 52.5% from current levels [6]